ClinicalTrials.gg
Status unknownNCT05409898SMARTUpdated Jun 8, 2022

Screening for Masked Hypertension With Smart Wearable Devices (SMART)

An observational study in Masked Hypertension, sponsored by Jing Liu. Status unknown at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-08.

Sponsored by Jing Liu · Observational

How we know

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 50 Years
Sex
All
01

Study summary

In recent years, a large number of consumer-grade and Smart Wearable Devices (SWD) such as smart watches, with BP measurement property, have entered the market and have a high configuration and utilization among young and middle-aged populations, but most of them are uncalibrated and have poor accuracy. Recently, several medical-grade smart BP watches have passed the national medical device registration test, which will provide an important tool for accurate screening of hypertension, especially masked hypertension, in young and middle-aged people.

"Screening for masked hypertension in young and middle-aged adults with smart wearable devices" (SMART)aims to screen for masked hypertension using smart BP watches that have been tested for national medical device registration. It is planned to include 200 young and middle-aged subjects with normal blood pressure (BP) in the clinic, who will wear the smart BP watch for 7 consecutive days (BP will be measured at least once in the morning and once in the evening, 2-3 times each time), and if the mean BP is >= 135/85 mmHg, it will be determined to be MK and recommended for further consultation and treatment.

Read the detailed description

Masked hypertension (MH) is defined as elevated ambulatory or home blood pressure (BP), but normal office BP, often complicated with severe cardiovascular and renal damage. MH is easily missed and needs to be identified by "out-of-office" BP measurements such as ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM). However, in clinical practice, ABPM has poor accessibility, high cost, and requires appointments, making it difficult to meet the demand; HBPM has better accessibility, but low utilization and irregular use are more prominent. In addition, these devices interfere with sleep and activity when measuring BP, so their clinical application is somewhat limited.

Smart wearable devices (SWD) can sense and record various physiological parameters of human body, and analyze the health status of individuals with the support of software algorithms. In recent years, a large number of consumer-grade and SWD such as smart watches, with BP measurement property, have entered the market and have a high configuration and utilization among young and middle-aged populations, but most of them are uncalibrated and have poor accuracy. Recently, several medical-grade smart BP watches have passed the national medical device registration test, which will provide an important tool for accurate screening of hypertension, especially MH, in young and middle-aged people.

"Screening for masked hypertension in young and middle-aged adults with smart wearable devices" (SMART) aims to screen for MH using smart BP watches that have been tested for national medical device registration. It is planned to include 200 young and middle-aged subjects with normal blood pressure in the clinic, who will wear the smart BP watch for 7 consecutive days (BP will be measured at least once in the morning and once in the evening, 2-3 times each time), and if the mean BP is >= 135/85 mmHg, it will be determined to be MK and recommended for further consultation and treatment.

02

Conditions studied

  • Masked Hypertension

Keywords

  • asked hypertension, Smart wearable device
03

In context

Lead sponsor

Jing Liu is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will be recruited in the hospital in the volunteers who are interested in this project or those who are concern of the hypertension despite with norm tension during usual physical examinations.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-50 years of age, male or female
  2. No clear previous history of hypertension and other cardiovascular diseases
  3. Signed form

Exclusion criteria

Exclusion Criteria:

  1. Patients with established hypertension
  2. History of severe heart, liver, or kidney disease
  3. Inability to cooperate in completing the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

  • Devicesmart wearable device

    screening masked hypertension with smart wearable devices

06

What researchers measure

Primary outcomes

  1. Prevalence of masked hypertension

    Average systolic/diastolic BP during 7 days of the observation period will be calculated. Office BP should be measured when the average BP is ≥135/85 mmHg during 7 days of continuous self-monitoring. If the office BP is \< 140/90 mmHg at visit, "Masked Hypertension" will be diagnosed. The prevalence of masked hypertension will be calculated as the following: number of masked hypertension/number of subjects included.

    Time frame: 7 days

Secondary outcomes

  1. Prevalence of hypertension

    Average systolic/diastolic BP during 7 days of the observation period will be calculated. Office BP should be measured when the average BP is ≥135/85 mmHg during 7 days of continuous self-monitoring. If the office BP is ≥140/90 mmHg at visit, the diagnosis will be "Hypertension". The prevalence of hypertension will be calculated as the following: number of hypertension/number of subjects included.

    Time frame: 7 days

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, 100044, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2022; primary completion for Jun 2024, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2022
First posted
Jun 8, 2022
StartEst.
Jul 2022
Primary completionEst.
Jun 2024
CompletionEst.
Jul 2024
Last update
Jun 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05409898
Lead sponsor
Jing Liu
Collaborators
HUAWEI
Responsible party
Jing Liu (Director of the Department of Hypertension, Peking University People's Hospital) — Sponsor-investigator
First posted
Jun 8, 2022
Start date
Jul 2022 (estimated)
Primary completion
Jun 2024 (estimated)
Completion
Jul 2024 (estimated)
Last update
Jun 8, 2022

Study contacts

Jing Liu, MD
Contact
heartcenter@163.com
01088325457
Jing Liu, MD
study chair · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion